Arecor Therapeutics PLC AREC

Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF) has cleared its final regulatory hurdle, with full MHRA approval secured for its TOPICAL trial across six UK sites. Interim data on its CRS therapy is expected this summer, with US payer research pointing to a big opportunity. Arecor Therapeutics PLC (AIM:AREC) is advancing its lead insulin candidate AT278, which it says outperforms best-in-class rivals for use in insulin pumps. A Phase 2 trial is targeted for the second half of 2026, backed by a partnership with Sequel Med Tech. hVIVO PLC (AIM:HVO) beat EBITDA guidance in 2025 and closed the

Arecor Therapeutics PLC (AIM:AREC) says talks are progressing on a broader partnership for its lead insulin candidate AT278. Releasing its 2025 annual results, the Cambridge-based diabetes biotech said a phase II trial is targeted for the second half of this year. Great Southern Copper PLC (LSE:GSCU, FRA:E9E) has expanded its footprint at the La Colorada prospect in Chile. Five new concessions add 1,000 hectares to what looks like a significant copper-gold target. Powerhouse Energy Group PLC (AIM:PHE, FRA:BT81) has granted a non-exclusive licence of its waste-to-energy technology to Hydrogen U

Arecor Therapeutics PLC's (AIM:AREC) CEO Sarah Howell talked with Proactive's Stephen Gunnion about the company’s second-half performance and its strategic priorities heading into 2026, highlighting progress across its dual focus on diabetes and oral peptide delivery. Howell explained that Arecor is a clinical-stage biopharmaceutical company focused on drug development and enhanced delivery in the cardiometabolic space. The company’s lead asset, AT278, is described as a “new unique best-in-class ultra-concentrated (500 U/mL) and ultra-rapid-acting insulin for the treatment of diabetes,” and is

Rainbow Rare Earths Ltd (AIM:RBW, ASX:RRE) says its Johannesburg pilot plant is performing to plan and has produced commercial-grade rare earth product. The company says the quality de-risks the project and supports plans to move further downstream. Cloudbreak Discovery PLC (LSE:CDS) shares jumped after it moved to buy 90% of the Paterson gold-copper project in Western Australia. The company plans modern geophysics to refine drill targets near Greatland Gold’s Telfer mine. Valereum PLC (LSE:VLRM) has signed an MoU with RWA.io and Defactor to explore compliant tokenised asset issuance and distr

Empire Metals Ltd (AIM:EEE, OTCQX:EPMLF) has reported strong progress at its Pitfield titanium project in Western Australia. Flotation and low-temperature leaching tests look positive, with studies underway toward a scoping study in 2026. Bradda Head Lithium Ltd (AIM:BHL, OTC:BHLIF, TSX-V:BHLI, FRA:8CD1) has agreed a lithium joint venture option with Rio Tinto’s Kennecott. If shareholders approve the deal, Braddahead said the Whistlejack project in Arizona would be a great acquisition and it plans to commence exploration as soon as possible. 88 Energy Ltd (AIM:88E, ASX:88E, OTCQB:EEENF, FRA:P

The UK market has recently faced challenges, with the FTSE 100 index closing lower due to weak trade data from China, highlighting global economic uncertainties. Despite these broader market fluctuations, penny stocks present unique opportunities for investors seeking growth potential in smaller or newer companies. Although the term 'penny stock' may seem outdated, these stocks can offer significant returns when backed by strong financials and solid fundamentals.

The London stock market has recently experienced turbulence, with the FTSE 100 and FTSE 250 indices closing lower amid concerns over weak trade data from China, impacting companies tied to its economic fortunes. In such fluctuating conditions, identifying stocks with solid fundamentals becomes crucial for investors seeking potential opportunities. Penny stocks, though often seen as a niche area of investment, can still offer growth prospects when they are backed by strong financial health and...